Sempra (SRE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual shareholders meeting is scheduled for May 13, 2025, in a virtual-only format to enhance accessibility and reduce environmental impact.
The company reported a 21% total shareholder return in 2024 and increased its five-year capital plan by 16% to $56 billion, with over 90% focused on regulated utilities.
Three new directors joined the board in 2024 and early 2025, reflecting ongoing board refreshment and commitment to diverse skills and perspectives.
Shareholder engagement remains a priority, with regular outreach and feedback incorporated into governance and compensation practices.
Voting matters and shareholder proposals
Shareholders will vote on the election of 11 director nominees, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory say-on-pay proposal for executive compensation.
The board recommends voting FOR all director nominees, auditor ratification, and executive compensation approval.
Shareholders representing at least 10% of outstanding shares may call a special meeting, and proxy access is available for director nominations.
Board of directors and corporate governance
82% of the board is independent, with an average tenure of 5.9 years and 64% diversity (women or people of color).
Annual board, director, and committee evaluations are conducted, with a strong focus on board refreshment and succession planning.
All NYSE-required committees are 100% independent, and a Lead Independent Director role provides robust oversight.
Directors are subject to share ownership guidelines and overboarding policies.
Latest events from Sempra
- $65B capital plan and record adjusted EPS drive sector-leading growth outlook.SRE
Q4 202526 Feb 2026 - Q2 2024 earnings rose to $713M, with strong Texas/California growth and major projects advancing.SRE
Q2 20242 Feb 2026 - Q3 EPS fell, but guidance and $3B equity plan reaffirmed; Texas and LNG drive growth.SRE
Q3 202416 Jan 2026 - Q1 2025 EPS up, guidance affirmed, and major asset sales and capital investment drive outlook.SRE
Q1 20258 Jan 2026 - 2024 adjusted EPS hit $4.65, with a $56B capital plan and 7–9% EPS growth targeted.SRE
Q4 20247 Jan 2026 - Director nominee Jennifer M. Kirk will become CEO of Exubrion Therapeutics in May 2025.SRE
Proxy Filing1 Dec 2025 - Virtual meeting to elect 11 directors, ratify auditor, and approve executive pay.SRE
Proxy Filing1 Dec 2025 - Q2 2025 adjusted EPS held steady as utility growth, LNG progress, and guidance advanced.SRE
Q2 202523 Nov 2025 - Adjusted EPS up, major asset sale and Texas/LNG growth drive strong long-term outlook.SRE
Q3 20255 Nov 2025